volrustomig + rilvegostomig + AZD0901 + AZD7789

This is an **investigational combination therapy** consisting of four novel agents developed by AstraZeneca, each with distinct immunotherapeutic or targeted mechanisms, under investigation for the treatment of advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. - **Volrustomig** is a bispecific monoclonal antibody targeting both PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), designed to enhance antitumor immunity by dual checkpoint inhibition. - **Rilvegostomig** is a bispecific monoclonal antibody that targets PD-1 and TIGIT (T cell immunoreceptor with Ig and ITIM domains), providing checkpoint blockade at two immune regulatory nodes to potentiate immune responses against tumors. - **AZD0901** is an antibody-drug conjugate (ADC) targeting Claudin 18.2, a clinically relevant surface protein highly expressed in certain gastric and pancreatic cancers; it delivers a cytotoxic payload (monomethyl auristatin E, MMAE) to Claudin 18.2-positive cancer cells, causing microtubule disruption and cell death, with additional activity via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). - **AZD7789** is a bispecific monoclonal antibody directed at PD-1 and TIM-3 (T cell immunoglobulin and mucin-domain containing-3), offering checkpoint inhibition to restore T cell function and enhance cancer immunosurveillance. This combination is being evaluated in an open-label phase 2 trial for efficacy and safety in subjects with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma[5][1].